BioSeek and Asterand said that the recent collaboration is a follow up agreement between both the companies for peptide screening and related drug discovery activities.
As per the agreement, BioSeek is expected to use BioMAP predictive human disease models to screen Amylin Pharma’s Phormol library to discover peptides with a potential to treat range of inflammatory conditions.
Being a primary cell-based models of human disease biology, BioMAP Systems are designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology.
Insight into human pharmacological and toxicological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds, will be provided by BioMAP.
Martyn Coombs, CEO of Asterand, said: “Our BioMAP human-based disease model is well-suited to assist Amylin in its search for new innovative treatments for inflammation. We look forward to assisting Amylin with this latest project, and other similar collaborations in the future.”
Asterand is a provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery, while Amylin Pharmaceuticals discovers, develops and commercialise medicines for the treatment of diabetes, obesity, and other metabolic diseases.